GILL QUARTERLY PUBLISHED BY UK GILL HEART & VASCULAR INSTITUTE - Winter 2020 - Internal Medicine
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
GILL QUARTERLY PUBLISHED BY UK GILL HEART & VASCULAR INSTITUTE Winter 2020
GILL QUARTERLY WINTER 2020-2021 TABLE OF CONTENTS Clinical Trials | Page 3 Fellows News/Accomplishments | Page 6 Affiliate News | Page 9 Features | Page 10 CV-RPA | Page 20 Current Research Funding | Page 22 Publications | Page 27
3 | Gill Quarterly, Winter 2020
FEATURED
CLINICAL TRIAL
RELIEVE-HF™ – Patients with heart failure
(HF) tend to have high pressure inside the left
side of their heart, including the left atrium
and the left ventricle, the main pumping chamber
of the heart. This often results in shortness of breath,
fatigue, and difficulty performing daily activities due
to pressure and fluid backup into the lungs. Many
patients with heart failure experience repeated hos-
pitalizations, poor quality of life, and a reduced life
expectancy.
PI: John Gurley, MD
determine the effects of the Interatrial Shunt device,
V-Wave Interatrial Shunt System in comparison to optimal conventional therapies,
V-Wave is a global medical device company on clinical outcomes that are important to HF paients.
dedicated to the treatment of heart failure. The These include reducing hospitalizations or emergency
company has developed a minimally invasive, room visits due to worsening HF, as well as improving
implanted device called the V-Wave Interatrial symptoms, exercise capacity, and quality of life.
Shunt for treating patients with HF.
The study is being performed at many centers around
The V-Wave Shunt is an hourglass shaped device that the world. Approximately 500 patients will be en-
is delivered through a catheter (a flexible plastic tube) rolled. Your doctor can discuss with you the criteria
inserted in a vein in the groin and implanted perma- for inclusion into the study as well as important in-
nently across the wall dividing the left and right atria formation about the testing and study procedures and
also known as the upper chambers of the heart. The the follow-up visits required.
procedure is performed in a hospital under sedation
or anesthesia and typically takes less than ninety Are You a Candidate?
minutes. You may be eligible for the RELIEVE-HF
study if you have:
How the Device Works
The V-Wave Interatrial Shunt is designed to reduce • Heart failure that causes noticeable symptoms such
excess left atrial and left ventricular pressure. In HF, as shortness of breath, fatigue, or difficulty performing
as pressure builds up, a small volume of blood is daily activities (defined as New York Heart Class III or
‘shunted’ from the left to the right atrium through the ambulatory Class IV HF)
device, thus relieving the elevated pressure and reduc-
ing fluid backup in the lungs. • A hospital admission for HF within the past12
months, or an elevation in a certain blood test for HF,
About the RELIEVE-HF Clinical Trial called BNP or NT-pro-BNP.
V-Wave has approval from the U.S. Food and Drug For More informatio contact: Stephanie Morris:
Administration(FDA) to conduct a large clinical study stephanie.a.morris@uky.edu
called the RELIEVE-HF Clinical Trial. The study will Phone: 859-323-5366
4 | UK Gill Heart & Vascular Institute
CURRENTLY ENROLLING
CLINICAL TRIALS
BIO LIBRA - AnaLysIs of Both Sex and Device care and cardiology practices.
Specific FactoRs on Outcomes in PAtients with
Non-Ischemic Cardiomyopathy Women’s IschemiA TRial to Reduce Events In
PI: Aaron Hesselson, MD Non-ObstRuctive CAD (WARRIOR)
Coordinator: Ben Rushing 323-5259 PI: Gretchen Wells, MD
Coordinator: Denise Sparks, RN 218-6713
Brief Summary:
This study is designed to evaluate the combined risk of Brief Summary:
all-cause mortality and treated ventricular tachycardia The Ischemia-IMT (Ischemia-Intensive Medical Treat-
(VT) or ventricular fibrillation (VF) events by subject ment Reduces Events in Women with Non-Obstruc-
sex and by implanted device type. All-cause mortality, tive CAD), subtitle: Women’s Ischemia Trial to Reduce
VT or VF alone, risk of cardiac death, and sudden car- Events in Non-Obstructive CAD (WARRIOR) trial is a
diac death will be analyzed for the total cohort, as well multicenter, prospective, randomized, blinded out-
as by subject sex and by the implanted device type come evaluation (PROBE design) evaluating intensive
statin/ACE-I (or ARB)/aspirin treatment (IMT) vs.
OPTIMIZER SMART POST - APPROVAL usual care (UC) in 4,422 symptomatic women pa-
STUDY tients with symptoms and/or signs of ischemia but
PI: Aaron Hesselson, MD no obstructive CAD. The hypothesis is that IMT will
Coordinator: Ben Rushing 323-5259 reduce major adverse coronary events (MACE) 20%
vs. UC. This study is being conducted to determine
Brief Summary: whether intensive medication treatment to modify risk
Post-approval study that evaluates data such as cardi- factors and vascular function in women patients with
ac outcomes, quality of life, mortality, and function- coronary arteries showing no flow limit obstruction
ality. Long-term data needed to assess complication but with cardiac symptoms (i.e., chest pain, shortness
rates and potential interactions with other implant- of breath) will reduce the patient’s likelihood of dying,
able devices in the intended patient population. having a heart attack, stroke/TIA or being hospitalized
The post-approval study (PAS) protocol designed to for cardiac reasons. The esults will provide evidence
address these concerns in a real-world setting. data necessary to inform future guidelines regarding
how best to treat this growing population of patients,
The PRECISE Protocol: Prospective Random- and ultimately improve the patient’s cardiac health
ized Trial of the Optimal Evaluation of Cardiac and quality of life and reduce health-care costs.
Symptoms and Revascularization (PRECISE)
PI: Vincent Sorrell, MD
Coordinator: Ben Rushing 323-5259
Brief Summary:
The study will be a prospective, pragmatic, random-
ized clinical trial of the comparative effectiveness of
diagnostic evaluation strategies for stable CAD, to be
performed in outpatient settings, including primary
5 | Gill Quarterly, Winter 2020
CLINICAL TRIALS CONTINUED
RELIEVE – HF - REducing Lung congestIon tiplatelet effects of ticagrelor with IV infusion of
symptoms using the v-wavE shunt in ad- PB2452 and the clinical efficacy of PB2452 by assess-
VancEd Heart Failure ment of hemostasis in ticagrelor-treated patients with
PI: John Gurley, MD uncontrolled major or life-threatening bleeding or
Coordinator: Stephanie Morris 323-5366 who are undergoing urgent surgery or invasive proce-
dure in a an open-label, single-cohort study.
Brief Summary:
The objective of this study is to provide reasonable For more information, contact:
assurance of safety and effectiveness of the V-Wave
Interatrial Shunt System to improve clinical outcomes Stephanie Morris, CCRP
in a certain high-risk subset of symptomatic patients Clinical Research Manager – Cardiovascular and Ra-
suffering from HF. diology Services
Gill Heart & Vascular Institute Clinical Research Or-
REVERSE-IT: A Phase 3, Multicenter, ganization
Open-Label, Single-Arm Study of PB2452 in Phone: 859-323-5366
Ticagrelor-Treated Patients with Uncontrolled Stephanie.A.Morris@uky.edu
Major or Life-Threatening Bleeding or Requir-
ing Urgent Surgery or Invasive Procedure Jennifer Isaacs, MS, MS, CCRP
PI: Ahmed Abdel- Latif, MD, PhD Clinical Research Director– Cardiovascular and Ra-
Coordinator: Jennifer Isaacs 323-4738 diology Services
Gill Heart & Vascular Institute Clinical Research Or-
Brief Summary: ganization
The study will demonstrate the reversal of the an- Phone: 859-323-4738
6 | UK Gill Heart & Vascular Institute FELLOWS NEWS/ACCOMPLISHMENTS KY-ACC POSTERS
7 | Gill Quarterly, Winter 2020
KY-ACC POSTERS
8 | | UK Gill Heart & Vascular Institute
FELLOWS NEWS AND
PUBLICATIONS Publications
Alnabelsi T, Annabathula R, Shelton J, Paran-
FELLOWS MATCH zino M, Faulkner SP, Cook B, Dugan AJ, Nerusu S,
Smyth SS, Gupta VA. Predicting in-hospital mortality
We are pleased to announce that the following appli- after an in-hospital cardiac arrest: a multivariate anal-
cants have been matched to the Cardiology Fellows ysis. Resuscitation Plus. Volume 4, December 2020,
program: 10003
9.
Name Medical School Ellison K, Hesselson A, Ayoub K, Leung S, Gurley J.
Jad Ballout American University of Beirut Retrieval of an infected leadless pacemaker. Heart-
Nakeya Dewaswala Lokmanya Tilak Municipal Rhythm Case Rep. 2020 Sep 2;6(11):863-866. doi:
Med College 10.1016/j.hrcr.2020.08.022. eCollection 2020 Nov.
Awa Drame St George’s University
Sara Klinger West Virginia School of Os Gupta VA, Alnabelsi TS, Shringi S, Leung SW,
teopathic Medicine Sorrell VL. Cardiovascular Risk After Sepsis: Under-
Ahmed Noor Windsor University standing the Role of Statin Indications and the Impact
Nicole Sbircea Lincoln Memorial University of Clinical Inertia on Prescribing Patterns. J Cardio-
DeBusk College of Osteopath vasc Pharmacol Ther. 2020 Nov;25(6):541-547. doi:
ic Medicine 10.1177/1074248420933395.
Saima Shikari-Dossaji New York Institute of Tech
nology College of Osteopathic Whiteside HL, Moliterno DJ. Coronary interven-
Medicine tions among patients with hepatic insufficiency:
Encouragement to avoid a jaundiced view. Catheter
Cardiovasc Interv. 2020 Oct 1;96(4):811-812. doi:
10.1002/ccd.29277.
Fellowship Websites:
Vascular:
https://surgery.med.uky.edu/surgery-vascu-
lar-fellows
CT Surgery:
https://surgery.med.uky.edu/surgery-cardio-
thoracic-surgery-fellowship
9 | Gill Quarterly, Winter 2020
AFFILIATE & OUTREACH NEWS
MERCY HEALTH – LOURDES HOSPITAL
UK HealthCare (UKHC) and Mercy Health – Lourdes
Hospital are announcing a new collaboration to ex- include a structural heart program that is the first
pand cardiovascular services in the Paducah area. and only in western Kentucky and Southern Illinois
to offer transcatheter mitral valve treatment utilizing
As the first hospital in far Western Kentucky to join the MitraClip. “It is thrilling that we are now able to
the UK Gill Heart & Vascular Institute’s Gill Affili- build on these milestones at Lourdes thanks to our
ate Network, Mercy Health – Lourdes Hospital now affiliation with the prestigious Gill Heart & Vascular
offers area residents the benefit of UK HealthCare Institute,” Ashley Britton, Lourdes’ director of cardio-
physicians’ expertise in subspeciality cardiovascular vascular services, said. “The expansive expertise and
services.- ment to expanding access to services and care capabilities at the University of Kentucky will go
investing in new technology and capabilities to meet far in providing our regional residents the care they
the needs of our growing community in efforts to need and deserve.”
enhance our mission of Making Communities Health-
ier,” said Matt Smith, Clark Regional Medical Center CRMC has been working diligently to improve the
chief executive officer. “We will keep the community cardiac services offered within the community. The
informed of the project’s progress, and thank you for providers and technology within the cardiac cath lab
your patience during the construction process.” will be able to diagnose and provide treatment for
“Today’s announcement, along with the growth of our heart blockages and other cardiac conditions without
cardiovascular offerings and new providers, positions a commute.
Lourdes as the area’s leader in heart care,” Michael
Yungmann, president of Mercy Health – Lourdes Hos- Read the full story here.
pital, said. “This collaboration extends UK’s impact
in our region so that our patients have access to the
university’s high quality, state-of-the-art emergent
cardiovascular care right in our community.”
Lourdes’ already robust cardiovascular services
10 | Gill Quarterly,Winter 2020
NEW RESEARCH IN
MARFAN SYNDROME
Hip Pain in Patients With Marfan Syndrome
Researchers at the University of study at UK will be a first-look at the Patients from Sheppard’s clinic who
Kentucky have received a $100,000 mechanisms involved in the onset of volunteer for the study will have
grant from The Marfan Foundation hip joint pain and cartilage degen- an MRI taken and have their gait
to assess how patients with Marfan eration in patients with Marfan analyzed in the UK Biodynamics
syndrome develop hip pain. syndrome. Laboratory. The strength, size and
amount of fat within their hip abduc-
The study will be conducted by Mary Nearly half of patients with Mar- tors will be measured, as well as the
Sheppard, an assistant professor of fan syndrome self-report hip joint corresponding effects on their hip
family medicine and surgery in the pain yet it is highly unrecognized by joint movement patterns, hip joint
UK College of Medicine, and Mi- clinicians. pain and cartilage health.
chael Samaan, an assistant professor
of biomechanics in the UK College of “This combination of potentially
Education Department of Kinesiolo- weak hip joint musculature and ab-
gy and Health Promotion. normal joint shape can lead to high “We will provide an understanding
amounts of hip joint loading during of how the hip joint functions during
walking, which may cause hip pain walking in patients with Marfan
Marfan syndrome is a genetic and cartilage breakdown,” Sheppard syndrome,” Samaan said.
condition that impacts the body’s said.
connective tissue. It most frequently
affects the heart, blood vessels, eyes The research team will take a closer
and bones. Diagnostic features can look at how the muscle weakness “We will provide an understanding
include a dilated aorta; dislocated associated with Marfan syndrome of how the hip joint functions during
lens; long arms, legs and fingers; leads to problems with hip joint walking in patients with Marfan
a curved spine; a chest that sinks muscle function, muscle morphol- syndrome,” Samaan said. “Our hope
in or sticks out; flat feet; and an ogy and gait mechanics. The exact is that this will allow clinicians to
abnormally shaped hip joint, among association of these factors with the develop treatments that can improve
others. onset of hip joint pain and cartilage hip muscle function, reduce hip joint
degeneration is unknown and of par- pain and reduce the risk of develop-
The cardiovascular impacts of hav- ticular interest to the researchers. ing hip osteoarthritis in people with
ing Marfan syndrome can be signifi- Marfan syndrome.”
cant, and have been the focus of the “A mechanistic assessment of the
majority of prior research. The effects of Marfan syndrome on the The researchers expect future
muscles and hip is needed because, studies will help create targeted
although patients with this syn- muscle-based therapies to reduce
“This combination of potentially drome have weak quadriceps and hip pain in people with Marfan syn-
weak hip joint musculature and ab- hamstring muscles, we do not know drome and related conditions.
normal joint shape can lead to high whether or not the muscles around
amounts of hip joint loading during the hip joint are affected by the syn-
walking, which may cause hip pain drome. Our project will determine
and cartilage breakdown,” Sheppard how hip joint muscle weakness, size,
said. and amount of fat within the mus-
2 | UK Gill Heart & Vascular Institute
The Marfan Foundation is a non- The grant awarded to Sheppard
profit organization that works to and the UK team is part of the Drs Sheppard and Samaan in the
save lives and improve the quality foundation’s 2020 research grant UK Biodynamics Laboratory.
of life for individuals and fam- program. The total amount of
research funded by this program
ilies with Marfan, Loeys-Dietz,
in 2020 is $1.4 million. For more
VEDS and other genetic aortic information, please visit www.
and vascular conditions through marfan.org.
research, education and support.
If you would like to learn
more about participating in
this study, please call Dr.
Mary Sheppard at 859-323-
3280.12 | Gill Quarterly, Winter 2020
JING LI ON BUILDING A CAREER
IN A NEW COUNTRY, QUALITY IMPROVEMENT AND
JUMPING ‘OUT OF THE BOX’BY UK VITAL SIGNS DECEMBER 2020
Jing Li came to the United States the program. Since coming to UK then work with them together.” So
from her hometown of Tianjin, Chi- HealthCare in January 2014, she has I gradually learned this skill, and I
na, in 2000 with a medical degree in overseen many quality-improvement would say that’s the lifetime lesson
anesthesiology, a master’s in clini- research projects and received major for me.
cal research and an anesthesiology funding from several prestigious
residency, all completed at Tianjin organizations, including the National VS: How do you foster self-growth
Medical University. Because of the Institutes of Health, Patient-Cen- outside of work?
expense of obtaining a U.S. medical tered Outcomes Research Institute, JL: I do a lot of self-reflection. If
license and lack of interest in repeat- and the CMS. I cannot do it on a daily basis, I at
ing another required residency, she least use the weekend to think about
pursued her passion for research. VS: If you could go back five or 10 what happened in the past week
years in your career, what would you and anything I really did well and
After completing a second master’s say to your younger self? should continue to do, and anything
in computer and information science JL: People think having a mentor I feel like I could do better or do a
at the University of Alabama at during their education and training different way. Sometimes I will talk
Birmingham, Li began working in is important. I would say if it is not with my friends and my mentors at
medical research at the UAB. Three more, it will be equally important to UK and outside of UK to ask their
years later, she was recruited by find a mentor at your work, espe- opinion and share some thoughts
the Alabama Quality Improvement cially for people just starting. A lot with them. And I like having a new
Organization, a contractor for the of times, for people coming out of project where I can push myself to
Centers for Medicare and Medicaid school, the education they receive learn new knowledge and skills.
Services seeking to improve quality is quite broad. [You need] to have
of care in a variety of service set- somebody work with you to figure VS: What is the most courageous
tings. out what you’re really passionate thing you have done?
about, and also help you to develop a JL: It’s a pretty bold decision to
Since then, Li has become an expert plan for yourself. move to another country. At that
in quality improvement. During a time, I had no idea how my career
stint at Northwestern University VS: What is one work or life expe- would be. I came alone and did not
in Chicago, she worked with Mark rience that you appreciate for the know anyone. I usually go back [to
Williams, MD, MHM, FACP, UK lessons you learned? China] every year [to visit family].
HealthCare’s current chief qual- JL: The first project I did at Alabama This year the pandemic stopped
ity and transformation officer. QIO under CMS contract, I was told everything. The good part right now
Together, they worked to expand [that] we were required to reduce is that with technology you can see
three quality improvement projects pressure ulcers at nursing homes. I family and so that helps.
to more than 60 hospitals across did my homework and I pulled the Also, I would say changing the job
Illinois. When Williams was recruit- data to see what worked at other from UAB to Alabama QIO. I made
ed by UK HealthCare to direct the places, but after three facilities told a decision considering my interests
Center for Health Services Research, me “No, that won’t work,” I went to and my future career, and it was
he asked Li to help him develop my manager at that time. My man- not an easy decision. As a foreign
ager told me, “You told them, ‘[You] person, we have this Visa limitation,
Jing Li, MD, DrPH, MS, Associate need to do better; this is what you so changing jobs is not easy and
Professor of Internal Medicine/Car- should do.’ You need to spend the reduces the time for you to apply for
diovascular Medicine and co-direc- time, understand their situation, and permanent residency status.
tor of the Center for Health Services
Research2 | UK Gill Heart & Vascular Institute
On a trip to China, Jing Li visited a
tea-leaf farm owned by a friend in Su-
zhou, where she learned the process
of picking and preparing the leaves to
be used in making tea.
VS: What was the hardest part all planned. Even when I was in “If you are lucky, you enjoy what
about moving to the United medical school, there were not you are doing. But there may be
States? many optional classes. In the 80% of your job you enjoy and
U.S., suddenly you have freedom then there is 20% you don’t. I
JL: We started to learn English
to choose what you learn; I would just think about why I’m doing
in my generation when I was in
say that’s amazing. it, and I think about the people I
elementary school. We have six work with, and most importantly
years in elementary school, so VS: What inspires you most in about the difference we can make
starting in year five, we start- life? through what we do.”
ed learning English, and then JL: When I started my internship
through middle school, high and residency back in China, I VS: Who is your role model?
school and college. But I got here worked at the largest hospital in JL: My older sister. I am amazed
and I still didn’t know how to talk my hometown. Even back then about her perseverance and re-
to people. It’s a little scary. Can it had over 1,000 beds, and a silience. She suffered severe burn
lot of outstanding professionals damage at work soon after high
people understand me, or am I
worked there. I heard amazing school, so she didn’t go to college.
saying the right words? When you stories about those people, [how] This required her to tolerate se-
talk with people, what topics are they built up the program with vere pain during the recovery,
appropriate and what are not? Af- a very poor infrastructure, and and she never complained. Amaz-
ter a little bit, you start knowing how hard they worked and what ingly she completed an associate
people, and people are really nice, type of research they did. You feel degree during her recovery time.
and they know you come from an- like you’ll never be able to reach She is always a hard worker and
other country; a lot of times they them, and then when you got an always cares about family. Unfor-
help you. opportunity to be on rounds with tunately, she was diagnosed with
them, you saw how they interact- lymphoma last year and under-
ed with patients, how they inter- went intensive chemotherapy.
VS: What was most exciting about
acted with colleagues and how But she maintains her optimism
moving to the United States?
they mentored trainees. They are and focuses on what she can do
JL: It’s a different learning style
human beings, and they do not and the good parts about life.
regarding the overall educa-
consider themselves as heroes.
tion. You are told those are the
That made me feel like I wanted VS: What are your strategies for
required courses and then the
to be one of those people; I want- dealing with stress and
others you feel free to choose
ed to be able to achieve the same difficult experiences at work?
whatever you want. In the edu-
level of accomplishments and JL: If you are lucky, you enjoy
cation system back in China, all
always try to be helpful to others. what you are doing. But there
the courses are prescribed and
may be 80% of your job you enjoy
and then there is 20% you don’t.14 | Gill Quarterly, Winter 2020
JING LI
CONTINUED
just think about why I’m doing it, VS: What do you enjoy doing Over time that teapot also ab-
and I think about the people I outside of work? sorbs the tea flavor. [It] needs to
work with, and most importantly JL: I’m more like an introverted be one type of tea for one teapot;
about the difference we can make person, and I’m OK establishing you can’t mix them together.
through what we do. Other times partnerships, relationships and When I do all these types of
I will talk with my mentors for I leading projects, but I need my things, it requires me to slow
guidance. Sometimes I will pur- downtime. Most of the time I down and be in focus on what
posely jump out of the box: I do drink tea. I collect teapots, and I’m doing, and I purely immerse
not want to talk about it; I do not so my kind of tea ceremony time, myself in the moment.
want to think about it. Just leave that’s my downtime to regain
it maybe for several days and energy. [My favorite tea] depends I also talk with my friends, and
then later come back and try to on on the different seasons and then I like cooking. [My favorite
look at it more from a thirdper- on the day. There is one type of dish is] a stir fry. I do not use a
son perspective and reassess the clay, and it’s only available in a recipe, so I just kind of see what
situation to see if there is any- small town in China and it can type of meat or seafood and what
thing I can do. help make the tea flavor better. type of vegetables I have in my
fridge. Then I will just be cre-
ative and do the combination by
myself.
VS: What do the Living DIReCT
(diversity, innovation, respect,
compassion, teamwork) values
mean to you in your own words?
JL: How I connect those together:
diverse and innovative [people]
can accomplish the most when
they demonstrate the respect and
the compassion for each other
and their colleagues. A lot of
times this respect and compas-
sion is part of the requirement
to be a team and to conduct
teamwork and be innovative and
generate good results.
______
During a tour of Suzhou, China,
Jing Li visited a teapot store
owned by a friend, who taught
her the basics of making the clay
teapots that she enjoys collecting.15 | UK Gill Heart & Vascular Institute
NEW FACULTY
Gbolahan O. Ogunbayo, MD
Assistant Professor of Medicine
Residency: Rochester General Hospital, NY
Cardiology Fellowship: University of Kentucky
Interventional Fellowship: University of Kentucky
Yuri Boyechko, MD
Assistant Professor of Medicine
Residency: University of Kentucky
Cardiology Fellowship: University of Tennessee Chatta-
nooga
Amit Arbune, MD, MHA, FACC
Assistant Professor of Medicine
Residency: North East Ohio Medical University
Cardiology Fellowship: Case Western Reserve University
ACI Fellowship: Yale University11 | UK Gill Heart & Vascular Institute AFFILIATE & OUTREARCH NEWS This year’s Gill Heart and Vascular Institute Affiliate Affiliate Network Medical Director, Dr. Rick Network annual meeting was held October 28-October McClure, stated, “With over 18 hospitals, the Gill 30. Despite moving to a virtual format, over 100 indi- Affiliate Network now spans from far eastern viduals attended the event. The conference featured a Kentucky to far western Kentucky. Converting keynote presentation from The Advisory Board as well the meeting to a virtual format allowed for great- as several first-time presentations, including Common er participation from all Network members and Themes in Cardiovascular Litigation and How to Mit- enhanced the opportunity for collaboration and igate Risk. In addition, representatives from MedAxi- networking among members.” om and Apex Innovations, companies whose services will soon be available to all Gill affiliates, provided an overview of the benefits and services they offer. UK’s own marketing development manager, Laura Baker, co-presented the session, Making the Most of Mar- keting Your Gill Heart Affiliation, with Many Prather, To see more photos from the meeting search Director of Marketing and Communications at Gill Twitter for #GAN2020. Affiliate, Lake Cumberland Regional Hospital. Gill
17 | UK Gill Heart & Vascular Institute OCTOBER GAN ANNUAL MEETING
GRAND MAESTRO AWARD
The Patient and Family Advisory Committee Kentucky Chapter of the American College of
was inspired to create a cookbook of heart- Cardiology
healthy, recipes to help patients and families Khaled Ziada, MD, Governor
with new cardiac diagnoses as they adjust Susan Smyth, MD, Immediate Past Governor
their lifestyles. Gretchen Wells, MD, PhD, Secretary/Treasurer
Steve Leung, MD, Annual Scientific Meeting
National Level Committee Chair
Eleftherios Xenos, Medical Director for the Tracy Macaulay, PharmD, Councilor
Midwest Vascular Collaborative Majd Makhoul, MD, Councilor
Vicki Gatz, Chair of the Vascular Technology Matthew Sousa, MD, FIT Liaison
Examination Assessment Committee Susan Smyth, MD, PhD, Honorable Maestro
Susan Smyth, President Association of Uni- Award
versity Cardiologists
Vincent Sorrell, Associate Editor JASE New programs
Alan Daugherty, Editor in Chief, ATVB Cardiovascular Research Priority Area
David Moliterno, MD, Editor in Chief, JACC: Cardio-oncology program
Cardiovascular Interventions Cardiac amyloidosis clinic
American Society of Echocardiography UK Researchers Identify COVID-19 Blood Clot-
Vincent Sorrell, Boadr of Directors ting Cause
Majd Makhoul, Committee Member
Bryana Levitan, Research Council In Memorial, Thomas F Whayne, Jr, MD19 | UK Gill Heart & Vascular Institute
DECEMBER
YEAR IN REVIEW
US News Best Regional Hospital Awards
High Performing in: Aortic Valve Surgery, Gretchen Wells, American Heart Associa-
Heart Failure, and Heart Bypass Surgery tion’s Council on Clinical Cardiology 2020
Women in Cardiology Mentoring Award
By the numbers
- $4.4 million in research funding as Thomas Tribble, Saha Award
principle investigators
- 226 publications Wally Whiteheart, NHLBI Outstanding Re-
- 35 active clinical trials searcher
- 18 affiliate partners
- 10 outreach sites, including a new Jing Li, Robert Wood Johnson Foundation
Frankfort adult congenital heart disease Research award
and structural heart services
- 600 hours of clinical and community Gbolahan Ogunbayo, Alpha Omega Alpha
education
Amber Bach, MJ Dickson Quality Nursing
Accreditations Care Award
Intersocietal Accreditation Commission (IAC)
- Echocardiography Hillary Nolan, the Karen Sexton Firestarter
- Nuclear cardiology Award
- Vascular testing
Sara Smith, 2020 Nightingale Preceptor
American Association of Cardiovascular and Award
Pulmonary Rehabilitation (AACVPR)
Aaron Greer, 2020 CVICU RN Clinical Ex-
Patient Experience Award – top 25% na- cellence Award
tionally
- Heart Station
- Cardiac Rehab
- CT Surgery
- 6 North20 | Gill Quarterly, Winter 2020
CV-RPA NEWS
GAME CHANGER THERAPY FOR HF PATIENTS
University prioritizes cardiovascular research to benefit
Kentuckians across the Commonwealth
LEXINGTON, Ky. (Oct. 27, 2020) — LVADs are typically used in end- failure medications are not contin-
Dr. Emma Birks, UK HealthCare’s stage heart failure patients as a ued or optimized after LVAD im-
heart failure section chief, is working therapy of last resort, most often as plantation. “We have come up with a
on a new treatment therapy that a bridge to transplant or destina- way to more effectively use a device
recovers the hearts of some patients tion therapy in patients considered that is already widely used and avail-
with advanced-stage chronic heart to have failed medical therapy for able, by using it as a platform to add
failure and ultimately cut down the advanced chronic heart failure. a drug regime designed to improve
number of heart transplants needed. their heart function.”
Birks’ team has found that instead
Birks’ study, “REmission from Stage of using LVADs as a temporary Of the 40 patients receiving the
D Heart Failure: RESTAGE-HF,” is solution, of sorts, it can be used in pump as a bridge to transplant or as
featured in the publication Circula- combination with aggressive medical destination therapy, 40% of them
tion. therapy and regular testing of under- achieved the highest end goal - to
lying myocardial function, to pro- live free from mechanical support
The multicenter study, involving 40 mote recovery of the patient’s own and heart transplantation one year
patients from six high-profile medi- heart, which ultimately can result in after an LVAD explant (device
cal centers across the United States, the patient recovering and the LVAD removed). More than 50% of the
tested myocardial recovery using a being removed. patients were explanted overall.
cardiovascular treatment tool called “This is significant because the RE-
ventricular assist devices (LVADs). “This could be a game-changer with STAGE-HF protocol was reproduc-
very positive implications,” Birks ible with explants in all six partici-
said. “Not only can patients resume pating sites,” Birks said. “We hope
a normal quality of life and avoid the this will result in implementation of
need for immunosuppressant drugs this strategy in other LVAD centers
associated with transplant surgery, with broader application.”
it also frees up a donor heart that
can be used for patients with greater Birks plans to focus on using the
needs.” LVAD as a platform to induce myo-
cardial recovery using this protocol
Previously, the rate at which this as a “Stage 1” base that centers could
occurs is reported as only 1-2% in more broadly adopt.
the national LVAD registry, but Birks
said that’s only because few medical “We have come up with a way to
centers prospectively test or look for more effectively use a device that is
evidence of recovery, and often heart already widely used and available,
by using it as a platform to add a
Emma Jane Birks, MD drug regime designed to improve
Section Chief Heart Failure, their heart function.”
Department of Cardiovascular
Medicine Emma Birks, MDRESEARCH FEATURE
DISRUPTION OF THE CIRCADIAN SYSTEM
Circadian disruption with constant light ex- What they found: Constant light exposure
posure exacerbates atherosclerosis in male exacerbated atherosclerosis in male, but not
ApolipoproteinE-deficient mice. Chalfant, female, ApoE-/- mice. Male ApoE-/- mice
JM, Howatt DA, Tannock, LR, Daugh- exposed to constant light had increased
erty A, Pendergast JS. Sci Rep. 2020 Jun serum cholesterol concentrations due to
18;10(1):9920. doi: 10.1038/s41598-020- increased VLDL/LDL fractions.
66834-9.
Why it matters: Taken together, these
Disruption of the circadian system caused data suggest that exacerbated dyslipidemia
by disordered exposure to light is pervasive may mediate atherosclerotic lesion forma-
in modern society and increases the risk of tion caused by constant light exposure.
cardiovascular disease. The mechanisms by
which this happens are largely unknown.
What they did: In this study, we deter-
mined the effects of light-induced circadian
disruption on atherosclerosis in ApoE-/-
mice. We induced severe disruption of circa-
dian rhythms by exposing ApoE-/- mice to
constant light for 12 weeks.
Visit : https://www.research.uky.edu/research-priorities-initiative-cardiovascu-
lar-diseases/cardiovascular-diseases for more information.
Please visit: https://redcap.uky.edu/redcap/surveys/?s=W4WY8DEHEH to join
the CV-RPA.Ahmed Abdel-Latif Donna Arnett Thick-Filament Regulation In Hu-
Lysophosphatidic Acid Mediates Genomewide Association Study man Heart Failure
Cardiac Inflammation After Acute of Lipid Response to Fenofibrate Washington State University
Infarction and Dietary Fat 07/01/19-06/30/22
National Heart Lung and Blood National Heart Lung and Blood
Institute Institute CRCNS: Multi-Scale Models of Pro-
08/01/17-07/31/22 12/01/07-02/28/21 prioceptive Encoding for Sensorim-
otor Control Emory University
Doug Andres Ken Campbell 09/16/16-05/31/2021
RIT1-Mediated Protection Fol- Multiscale Modeling of Inherited
lowing Traumatic Brain Injury Cardiomyopathies and Therapeu- Lisa Cassis
National Institute of Neurological tic Interventions Center of Research in Obesity and
Disorders & Stroke National Heart Lung and Blood Cardiovascular Disease COBRE
02/15/2018-01/31/23 Institute Core A: Admin
08/03/17-07/31/22 Core National Institute of General
G-protein Signaling Reduces Medical Sciences
Neurodegeneration and Promotes Length-Dependent Activation in 09/08/08-07/31/23
Recovery of Synaptic Strength Human Myocardium
following Traumatic Brain Injury National Heart Lung and Blood Supplemental Environmental Proj-
KY Spinal Cord and Head Injury Institute ect Compliance Assistance Tools
Research Trust 09/15/20- 07/31/24 and Services
01/15/17-01/14/21 KY Department of Environmental
Dual Filament Control of Myocar- Protection
RIT1 as Novel Driver Oncogene in dial Power and Hemodynamics 07/01/07-12/31/21
Lung Adenocarcinoma University of Missouri
KY Lung Cancer Research Fund 08/25/20- 07/31/24 EPSCoR Administrative
07/01/16-06/30/21 KY Economic Development Cab
Computer Modeling of Myosin 02/01/19-06/30/22
An Innovative Therapeutic Ap- Binding Protein C and its Effect
proach to Treat Cardiomyopathy on Cardiac Contraction
Army Medical Research and Ma- Case Western Reserve
teriel Command 04/01/19-03/31/23
07/01/20-06/30/2323 | Gill Quaterly Winter 2020
RESEARCH FUNDING
CONTINUED
Healthy Kentucky Research Building Circadian Clock Regulation of Myo- A Novel Mechanism by which
Fit-up for Vascular Research cardial Ion Channel Expression and Smooth Muscle BMAL1 Regulates
Office of the Director Function IL-6 and Sexual Dimorphism of
09/23/19-10/31/21 University of Florida Abdominal
09/01/20- 05/31/21 Aortic Aneurysm
Sex Differences in Angiotensin-In- National Heart Lung and Blood
duced Vascular Diseases Tbx3-regulated Alternative RNA Institute
National Heart Lung and Blood Processing in Cardiac Conduction 08/20/18-07/31/22
Institute System Development
03/21/12-05/31/21 Geisinger Health System Scott Gordon
04/15/16- 03/31/21 The Role of High Density Lipopro-
Richard Charnigo tein Associated Protease Inhibitor
Almost-Smooth Nonparametric Re- Florin Despa Activity in Protection Against Ath-
gression and Pattern Recognition The Amylin Dyshomeostasis Hy- erosclerosis.
12/14/16-11/13/20 pothesis of Vascular Contributions to National Heart Lung and Blood
Cognitive Impairment and Dementia Institute
Alan Daugherty (VCID) 08/20/18-07/31/21
University of Kentucky- Baylor National Institute of Neurological
College of Medicine Aortopathy Re- Disorders & Stroke Protease Activity in Atherosclerotic
search Center 04/01/20-03/31/25 Plaque Formation and Protection
American Heart Association by Novel HDL-targeting Protease
04/01/18-03/31/22 Programing Amylin Secretion to Inhibitors
Slow Brain Aging - An Animal Model Medical Foundation
Adventitial-Medial Interactions in National Institute of Aging 12/01/18-11/30/20
Thoracic Aortic Diseases 09/15/17-04/30/22
American Heart Association High Density Lipoprotein Targeting
06/01/16- 05/31/21 Role of Systemic Amylin Dysho- Protease Inhibitors for Preserva-
meostasis in Alzheimer’s Disease tion of Lung Function
Macrophage Migration Inhibitory National Institute on Aging Alpha One Foundation Inc.
Factor and Urinary Pain 09/15/16- 05/31/21 07/01/19-12/31/20
Lexington Biomedical Research
Institute Ming Gong Gregory Graf
07/01/19-06/30/23 Targeting Timing of Food Intake Contributions of hepatic and
as a Novel Strategy against Disrup- intestinal pathways to cholesterol
Brian Delisle tion of Blood Pressure Circadian excretion
Transcriptional Regulation of Rhythm in Diabetes National Institute Diabetes &
KCNH2 National Heart Lung and Blood Digestive & Kidney
National Heart Lung and Blood Institute 09/13/17-07/31/22
Institute 01/15/19-10/31/22
03/08/19-02/28/2324 | Gill Quarterly, Winter 2020
RESEARCH FUNDING
CONTINUED
Bernhard Henning A Novel Mechanism of Immuno- Debra Moser
Nutrition and Superfund Chemical suppression in Sepsis: Depletion of Rural Intervention for Caregivers’
Toxicity Monocytes and Macrophages Heart Health (RICHH)
National Institute of Environmental National Institute of General Medi- National Institute of Nursing Re-
Health Sciences cal Sciences search
04/01/97-01/31/25 09/20/19-06/30/23 09/26/16-06/30/21
Brian Jackson Heart-Platelet Crosstalk: JNK, AFib, Online Cognitive Behavioral
Graduate Research Fellowship Pro- and Thrombogenesis Therapy for Depressive Symptoms
gram Rush University Medical Center in Rural Coronary Heart Disease
National Science Foundation 05/15/19-02/28/23 Patients
08/01/18-07/31/23 Patient Centered Outcomes Re-
Analia Loria search Institute
Jing Li Effect of Early Life Stress on Obesi- 10/01/2020 to 09/30/2024
Project MISSION: Developing a ty-Induced Hypertension in Mice
multicomponent, Multilevel Imple- National Heart Lung and Blood Gia Mudd-Martin
mentation Strategy for Syncope Institute Corazón de la Familia (Heart of the
OptImalCare thrOugh eNgagement 12/01/17-11/30/22 Family)
National Heart Lung and Blood National Institute of Nursing Re-
Institute Fat Nerve Recording in Mice search
08/15/18-07/31/21 American Physiological Society 03/02/17-01/31/22
10/01/19-07/31/21
Xiangan Li Heart of the Family: A Cardiovas-
Mechanism of Adrenal Insufficiency Hong Lu cular Disease and Type 2 Diabetes
as A Risk Factor for Sepsis Atherosclerosis Mechanisms: Angio- Risk Reduction Intervention in
National Institute of General Medical tensin II Production and Action High-Risk Rural Families
Sciences National Heart Lung and Blood National Institute of Nursing Re-
09/01/17-08/31/21 Institute search
05/01/18-03/31/22 09/07/20- 06/30/25
Synthetic HDL a Potential Sepsis
Therapy Andrew Morris Timothy Mullett
National Institute of General Medi- Define the Twist-ATX-LPAR1 Using Biomarkers and Imaging in
cal Sciences Signaling Axis in Promoting Obe- Fungal Regions to Improve Lung
11/01/15-11/30/21 sity-Associated Triple Negative Cancer
Breast Diagnosis Vanderbilt University
Zhenyu Li Cancer Army Medical Research and 04/01/19-03/31/21
Inflammasome Activation Triggers Materiel Command
Systemic Coagulation in Sepsis 04/15/16-04/14/21 Kentucky Lung Cancer Survivorship
National Heart Lung and Blood
Program
Institute Anniston Community Health Sur- Bristol Myers Squibb Foundation
05/15/19-04/30/23 vey: Follow-up Study and Dioxin Incorporated
Analyses 09/01/14- 02/28/21
National Cancer Institute
05/01/19-04/30/2125 | Gill Quarterly, Winter 2020
RESEARCH FUNDING
CONTINUED
Mariana Nikolova-Karakashian NRSA Training Core (Kentucky SBIR: Development of a TransApical
Ceramide and Acute Phase Proteins Center for Clinical and Translational to Aorta Double Lumen Cannula for
Elevation During Aging Science) a Neonate LVAD
National Institute on Aging National Center for Advancing W-Z Biotech LLC
08/01/02-05/31/23 Translational Sciences 04/01/19-07/31/21
08/15/16-05/31/21
Jonathan Satin Shuxia Wang
Monomeric G-Proteins and Cardio- Venkateswaran Subramanian Thrombospondin 1 in obesity associ-
protection from Heart Failure Calpains and Abdominal Aortic ated inflammation and insulin resis-
National Heart Lung and Blood Aneurysms tance National Institute Diabetes
Institute National Heart Lung and Blood & Digestive & Kidney
09/01/17- 08/31/21 Institute 08/20/17-05/31/21
08/10/17-07/31/21
An Innovative Therapeutic Approach Christopher Mark Waters
to Treat Cardiomyopathy Ryan Temel Biophysical Mechanisms of Hyper-
Army Medical Research and Materiel TRAF6 Nanoimmunotherapy to oxia-Induced Lung injury
Command Resolve Plaque Inflammation National Heart Lung and Blood
07/01/20- 6/30/23 Mount Sinai Institute
08/15/18-06/30/21 04/15/20- 03/31/24
Nancy Schoenberg
Community to Clinic Navigation to Targeting MicroRNA-33 To Reduce ASK1 and Ventilator-Induced Lung
Improve Diabetes Outcomes Intracranial Atherosclerosis and Injury
National Institute Diabetes & Diges- Other Neurovascular Hallmarks of National Heart Lung and Blood
tive & Kidney Vascular Cognitive Impairment and Institute
08/01/17-07/31/22 Dementia 12/15/16-11/30/20
National Institute of Neurological
Implementing an Evidence-Based Disorders & Stroke Regulation and Function of IL33
mHealth Diet and Activity Interven- 04/01/19-03/31/21 During Neonatal RSV Infection
tion: Make Better Choices 2 for Rural Louisiana
Appalachians Therapeutic Targeting of Metabolic State University
National Heart Lung and Blood microRNAs as a New Treatment 05/05/18-07/31/21
Institute Paradigm for NASH
08/01/20- 04/30/25 Aalborg University Nancy Webb
01/01/19-12/31/24 Serum Amyloid A, Inflammasome
Susan Smyth Activation, and Abdominal Aortic
Lipid Phosphate Phosphatase 3 as a Dongfang Wang Aneurysms
Novel Atherosclerosis Suppressor Development of a Paracorporeal National Heart Lung and Blood
National Heart Lung and Blood Pump-Integrated Artificial Lung for Institute
Institute Transport of Warfighters with Acute 01/01/17-12/31/21
04/01/15-03/31/21 Respiratory Distress Syndrome
(ARDS)
Army Medical Research and Materiel
Command
08/15/19 -08/14/2226 | Gill Quarterly, Winter 2020
RESEARCH FUNDING
CONTINUED
NRSA T32: Pharmacology and Jonathan Wenk Jeremy Wood
Nutritional Sciences: Multidisci- Force Validated Heart Valve Sur- Protein S Anticoagulant Activity:
plinary Approaches for Metabolic gical Planning Tool Biochemical Mechanisms and
Disease National Institute Diabe- University of Arkansas Structural
tes & Digestive & Kidney 09/01/19-08/31/22 Studies National Heart Lung and
08/15/00-07/31/21 Blood Institute
Sidney Whiteheart 09/15/15-03/31/21
Platelet Exocytosis and Endocyto-
sis in Thrombosis and Immunity
National Heart Lung and Blood
Institute
04/01/20-03/31/28
SEMINARS AND
JOURNAL CLUBS
* Please note if these seminars are still occurring, they will be online only. Check website for details.
Cardiovascular Seminar Series
Fridays at 8:00 am
This forum brings to campus prominent external speakers and provides presentations by UK faculty to ensure their
research expertise is widely known.
https://cvrc.med.uky.edu/cvrc-current-seminar-schedule
Cardiovascular Journal Club
Tuesdays at 8:00 am
Presenters in this forum discuss specific citations including basis for this publication's selection, strengths and
weaknesses, from the perspective as if he/she were the original reviewer. For more information contact:
Greg Graf, Ph.D. or Ryan Temel, Ph.D.
https://cvrc.med.uky.edu/cvrc-current-journal-club-schedule
Blood Cell Journal Club
4th Friday of each month at 4:00 pm
The journal club was started a number of years ago in an effort to provide a focal point for the hemostasis community
at UK. The focus is usually on platelets but they also discuss papers on Coagulation and Immune responses.
https://cvrc.med.uky.edu/cvrc-blood-cell-journal-club-201827 | Gill Quarterly, Winter 2020
PUBLICATIONS
OCTOBER-DECEMBER
Abo-Aly M, George B, Shokri E, AlSiraj Y, Thatcher SE, Blalock E, Bonaroti AR, Edmunds RW,
Chelvarajan L, El-Helw M, Smyth Saintilnord WN, Daugherty A, Lu DeCoster RC, Liau JY, Sekela
SS, Abdel-Latif A, Ziada K. Cangre- HS, Luo W, Shen YH, LeMaire SA, ME, Vasconez HC. Cardioplas-
lor in addition to standard therapy Arnold AP, Cassis LA. Monosomy tic Approach to Omental Flap
reduces cardiac damage and inflam- X in Female Mice Influences the Re- Coverage for Severe Aortic Root
matory markers in patients with gional Formation and Augments the Infections in the Opioid Era. Plast
ST-segment elevation myocardial Severity of Angiotensin II-Induced Reconstr Surg Glob Open. 2020
infarction. J Thromb Thrombolysis. Aortopathies. Arterioscler Thromb Oct 28;8(10):e3197. doi: 10.1097/
2020 Nov 30. doi: 10.1007/s11239- Vasc Biol. 2020 Oct 15:ATVBA- GOX.0000000000003197.
020-02345-8. HA120314407.
Bryan DS, Ferguson MK; members
Ai AL, McMullen CA, Smyth SS. Badia D, Hillard B, Ritchie C, of the Delphi Lobectomy Cooper-
Preoperative Optimism Related to Miller MD, Orr N, Tyagi S. Ureter- ative (Meyerson SL). Consen-
Low Anxiety in Patients 1 Month Af- al Arterial Fistula - A Role for Open sus for Thoracoscopic Left Upper
ter Open Heart Surgery. J Nerv Ment Operation in the 21st Century. Ann Lobectomy-Essential Components
Dis. 2020 Dec;208(12):966-973. doi: Vasc Surg. 2020 Dec 14:S0890- and Targets for Simulation. Ann
10.1097/NMD.0000000000001236. 5096(20)31020-7. doi: 10.1016/j. Thorac Surg. 2020 Oct 27:S0003-
avsg.2020.10.032. 4975(20)31739-2. doi: 10.1016/j.
Ai AL, Smyth SS. Depression After athoracsur.2020.06.152.
Open Heart Surgery: Influences of Beavers CJ, Wayne NB.Osocimab:
Optimism, Sex, and Event-Relat- A Novel Agent in Preventing Ve- Chalfant JM, Howatt DA, Tan-
ed Medical Factors. J Nerv Ment nous Thromboembolism. J Cardio- nock LR, Daugherty A, Pender-
Dis. 2020 Dec 11. doi: 10.1097/ vasc Pharmacol. 2020 Oct 1. doi: gast JS. Circadian disruption with
NMD.0000000000001285. 10.1097/FJC.0000000000000921. constant light exposure exacerbates
atherosclerosis in male Apolipo-
Al-Darraji A, Donahue RR, Tripathi Birks EJ, Drakos SG, Patel SR, protein E-deficient mice. Scientific
H, Peng H, Levitan BM, Chelvara- Lowes BD, Selzman CH, Starling RC, Reports 2020 10(1): 9920.
jan L, Haydar D, Gao E, Henson D, Trivedi J, et al. A Prospective Multi-
Gensel JC, Feola DJ, Venditto VJ, centre Study of Myocardial Recovery Chung ML, Lee SJ, Son YJ, Miller
Abdel-Latif A. Liposomal delivery Using Left Ventricular Assist Devices JL, King RB. Depressive Symptom
of azithromycin enhances its immu- (REmission from Stage D Heart Fail- Trajectories in Family Caregivers
notherapeutic efficacy and reduces ure: RESTAGE-HF): Medium Term of Stroke Survivors During First
toxicity in myocardial infarction. Sci and Primary Endpoint Results. Cir- Year of Caregiving. J Cardiovasc
Rep. 2020 Oct 6;10(1):16596. doi: culation. 2020 Oct 26. doi: 10.1161/ Nurs. 2020 Nov 25. doi: 10.1097/
10.1038/s41598-020-73593-0. CIRCULATIONAHA.120.046415. JCN.0000000000000773.
Alnabelsi T, Annabathula R, Bohnen JD, George BC, Clark JA, Sewanan LR, Schwan J,
Shelton J, Paranzino M, Faulkner Zwischenberger JB, Kendrick Kluger J, Campbell KS, Camp-
SP, Cook B, Dugan AJ, Nerusu S, DE, Meyerson SL, Schuller MC, bell SG. Fast-relaxing cardiomyo-
Smyth SS, Gupta VA. Predicting Fryer JP, et al. Trainee Autonomy in cytes exert a dominant role in the
in-hospital mortality after an in-hos- Minimally Invasive General Surgery relaxation behavior of heteroge-
pital cardiac arrest: a multivariate in the United States: Establishing a neous myocardium. Arch Biochem
analysis. Resuscitation Plus. Volume National Benchmark. J Surg Educ. Biophys. 2020 Nov 30:108711. doi:
4, December 2020, 100039. 2020 Nov-Dec;77(6):e52-e62. doi: 10.1016/j.abb.2020.108711.
10.1016/j.jsurg.2020.07.033.28 | Gill Quarterly, Winter 2020
PUBLICATIONS
CONTINUED
Conrad SA, Wang D. Evaluation Elbadawi A, Albaeni A, Elgendy IY, Fenton KN, Novick WM, Entwistle
of Recirculation During Venove- Ogunbayo GO, Jimenez E, Corn- JW 3rd, Moffatt-Bruce SD, Sade
nous Extracorporeal Membrane well L, Chatterjee A, et al. Tran- RM; Cardiothoracic Ethics Forum
Oxygenation Using Computation- scatheter Versus Surgical Aortic (Zwischenberger JB). Global
al Fluid Dynamics Incorporat- Valve Replacement in Patients health initiatives in cardiothoracic
ing Fluid-Structure Interaction. With Prior Mediastinal Radiation. surgery: Ethical considerations
ASAIO J. 2020 Dec 9. doi: 10.1097/ JACC Cardiovasc Interv. 2020 Nov and guidelines. J Thorac Cardio-
MAT.0000000000001314. 23;13(22):2658-2666. doi: 10.1016/j. vasc Surg. 2020 Oct 10:S0022-
jcin.2020.08.010. 5223(20)31320-9. doi: 10.1016/j.
Delisle BP, Stumpf JL, Wayland jtcvs.2020.05.084.
JL, Johnson SR, Ono M, Hall D, Elbadawi A, Elgendy IY, Megaly M,
Burgess DE, Schroder EA. Circadian Elzeneini M, Mentias A, Omer M, Fenton KN, Novick WM, En-
clocks regulate cardiac arrhythmia Ogunbayo G, Rai D, Drachman twistle JW 3rd, Moffatt-Bruce SD,
susceptibility, repolarization, and DE, Shishehbor MH. Temporal Sade RM; Cardiothoracic Ethics
ion channels. Curr Opin Pharmacol. trends and outcomes of critical Forum (Zwischenberger JB).
2020 Nov 9;57:13-20. doi: 10.1016/j. limb ischemia among patients with Global Health Initiatives in Car-
coph.2020.09.015. chronic kidney disease. Vasc Med. diothoracic Surgery: Ethical Con-
2020 Oct 1:1358863X20951270. doi: siderations and Guidelines. Ann
Deng P, Wang C, Wahlang B, Sexton 10.1177/1358863X20951270. Thorac Surg. 2020 Oct 14:S0003-
T, Morris AJ, Hennig B. Co-expo- 4975(20)30750-5. doi: 10.1016/j.
sure to PCB126 and PFOS increases Elbadawi A, Mahtta D, Elgendy IY, athoracsur.2020.05.010.
biomarkers associated with cardio- Saad M, Krittanawong C, Hira RS,
vascular disease risk and liver injury Omer M, Ogunbayo GO, et al. Ferraris VA. Why Is MIDCAB
in mice. Toxicol Appl Pharmacol. Trends and Outcomes of Fibrinolytic the Least Likely Option for Cor-
2020 Oct 20:115301. doi: 10.1016/j. Therapy for STEMI: Insights and onary Revascularization? Ann
taap.2020.11530. Reflections in the COVID-19 Era. Thorac Surg. 2020 Oct 21:S0003-
JACC Cardiovasc Interv. 2020 Oct 4975(20)31725-2. doi: 10.1016/j.
Di Francesco A, Choi Y, Bernier 12;13(19):2312-2314. doi: 10.1016/j. athoracsur.2020.07.086.
M, Zhang Y, Diaz-Ruiz A, Aon MA, jcin.2020.07.004.
Kalafut K, Ehrlich MR, Murt K, Ali A, Ge Y, Steel K, Antiochos P, Bing-
Pearson KJ, et al. NQO1 protects Ellison K, Hesselson A, Ayoub ham S, Abdullah S, Mikolich JR,
obese mice through improvements K, Leung S, Gurley J. Retrieval Arai AE, Bandettini WP, Shanbhag
in glucose and lipid metabolism. of an infected leadless pacemaker. SM, Patel AR, Farzaneh-Far A,
NPJ Aging Mech Dis. 2020 Nov HeartRhythm Case Rep. 2020 Sep Heitner JF, Shenoy C, Leung SW,
19;6(1):13. doi: 10.1038/s41514-020- 2;6(11):863-866. doi: 10.1016/j. et al. Stress CMR in patients with
00051-6. hrcr.2020.08.022. eCollection 2020 obesity: insights from the Stress
Nov. CMR Perfusion Imaging in the
Elbadawi A, Ahmed HMA, Elgen- United States (SPINS) registry. Eur
dy IY, Omer MA, Ogunbayo GO, Heart J Cardiovasc Imaging. 2020
Abohamad S, Paniagua D, Jneid Nov 9:jeaa281. doi: 10.1093/ehjci/
H. Outcomes of Acute Myocardial jeaa281.
Infarction in Patients with Rheu-
matoid Arthritis. Am J Med. 2020
Oct;133(10):1168-1179.e4. doi:29 | Gill Quarterly, Winter 2020
PUBLICATIONS
CONTINUED
Gunn TM, Gurley JC, Kesha- Ito M, Ye X, Wang Q, Guo L, Hao Krishnaswami A, Beavers C,
vamurthy S. Cannula migration D, Howatt D, Daugherty A, Cai L, Dorsch MP, Dodson JA, Masterson
through an undiagnosed patent Temel R, Li XA. SR-BI (Scavenger Creber R, Kitsiou S, et al. Inno-
foramen ovale and embolic cerebro- Receptor BI), Not LDL (Low-Density vations, Cardiovascular Team and
vascular accident in a patient with Lipoprotein) Receptor, Mediates Ad- the Geriatric Cardiology Councils,
femoral venoarterial extracorporeal renal Stress Response-Brief Report. American College of Cardiology.
membrane oxygenation. J Card Arterioscler Thromb Vasc Biol. Gerotechnology for Older Adults
Surg. 2020 Jul;35(7):1681-1682. doi: 2020 Aug;40(8):1830-1837. doi: With Cardiovascular Diseases:
10.1111/jocs.14618. 10.1161/ATVBAHA.120.314506. JACC State-of-the-Art Review.
J Am Coll Cardiol. 2020 Dec
Gupta VA, Alnabelsi TS, Shrin- Jackson NA, Gan T, Davenport 1;76(22):2650-2670. doi: 10.1016/j.
gi S, Leung SW, Sorrell VL. DL, Oyler DR, Ebbitt LM, Evers jacc.2020.09.606.
Cardiovascular Risk After Sepsis: BM, Bhakta AS. Preoperative opioid,
Understanding the Role of Sta- sedative, and antidepressant use is Leung SW. Are there ethnic
tin Indications and the Impact associated with increased postop- differences in coronary volume
of Clinical Inertia on Prescribing erative hospital costs in colorectal and myocardial mass? If so, what
Patterns. J Cardiovasc Pharmacol surgery. Surg Endosc. 2020 Oct 9. does it mean? J Cardiovasc Com-
Ther. 2020 Nov;25(6):541-547. doi: doi: 10.1007/s00464-020-08062-w. put Tomogr. 2020 Nov 4:S1934-
10.1177/1074248420933395. 5925(20)30469-X. doi: 10.1016/j.
Johnson EG, Nguyen J, Oyler D, jcct.2020.10.004.
Gwag T, Reddy Mooli RG, Li D, Lee Davenport DL, Endean E, Tyagi
S, Lee EY, Wang S. Macrophage-de- S. Naloxone Continuous Infusion for Li J, Gupta V, Smyth SS, Cow-
rived thrombospondin 1 promotes Spinal Cord Protection in Endovas- ley A, Du G, Sirrine M, Stearley S,
obesity-associated non-alcoholic cular Aortic Surgery Leads to Higher Chadha R, Bhalla V, Williams MV.
fatty liver disease. JHEP Rep. 2020 Opioid Administration and More Value-based syncope evaluation and
Oct 9;3(1):100193. doi: 10.1016/j. Pain. J Cardiothorac Vasc Anesth. management: Perspectives of health
jhepr.2020.100193. eCollection 2021 2020 Nov 24:S1053-0770(20)31278- care professionals on readiness,
Feb. 7. doi: 10.1053/j.jvca.2020.11.043. barriers and enablers. Am J Emerg
Med. 2020 Sep;38(9):1867-1874.
Hassan Z, Nisiewicz MJ, Ueland W, Kapoor H, Lee JT, Orr NT, doi: 10.1016/j.ajem.2020.05.029.
Plymale MA, Plymale MC, Daven- Nisiewicz MJ, Pawley BK,
port DL, Totten CF, Roth JS. Pre- Zagurovskaya M. Minimal Aor- Li L, Weiss HL, Li J, Chen Z, Donato
operative opioid use and incidence of tic Injury: Mechanisms, Imaging L, Evers BM. High plasma levels of
surgical site infection after repair of Manifestations, Natural History, pro-NT are associated with increased
ventral and incisional hernias. Sur- and Management. Radiographics. colon cancer risk. Endocr Relat Can-
gery. 2020 Nov;168(5):921-925. doi: 2020 Oct 2:200066. doi: 10.1148/ cer. 2020 Nov;27(11):641-646. doi:
10.1016/j.surg.2020.05.048. rg.2020200066. 10.1530/ERC-20-0310.
Kong Y, Zhang Y, Mao F, Zhang Z, Li
Z, Wang R, Liu J, Liu X. Inhibition
of EZH2 enhances the antitumor
efficacy of metformin in prostate
cancer. Mol Cancer Ther. 2020
Oct 6:molcanther.0874.2019. doi:
10.1158/1535-7163.MCT-19-0874.You can also read
